Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060684 · ClinicalTrials.gov registry record · Phase 1
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00060684: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT00060684 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060684, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
Interventions
- DRUG fludarabine
- DRUG dexamethasone
- DRUG rituximab
- DRUG Pixantrone (BBR 2778)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060684
The ClinicalTrials.gov registry entry for NCT00060684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fludarabine is the first listed.
NCT00060684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060684 about?
NCT00060684 is a clinical study titled "Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma". The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
What is the current status of trial NCT00060684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2001-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00060684?
The interventions under investigation include: fludarabine (DRUG), dexamethasone (DRUG), rituximab (DRUG), Pixantrone (BBR 2778) (DRUG).
Who is sponsoring clinical trial NCT00060684?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.